RecruitingPhase 1NCT05197530

Imaging of Lymphatic Vessels in People With Rheumatoid Arthritis (RA)

Near InfraRed Fluorescence Imaging of Lymphatic Transport Using Indocyanine Green: Phase II Pilot

Sponsor

University of Rochester

Enrollment

40 participants

Start Date

Dec 30, 2021

Study Type

INTERVENTIONAL

Conditions

Rheumatoid Arthritis

Summary

Lymphatic transport was previously examined by these investigators using Near InfraRed Indocyanine Green fluorescence imaging (NIR-ICG) of the upper extremities. They established reliable and reproducible methodologies in RA patients. The purpose of this phase 2 pilot is to study RA disease progression and effectiveness as well as the mechanism of action of clinical interventions using established NIR-ICG methodologies in previous studies.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using special imaging techniques to look at the lymphatic vessels (part of the immune system) in people with rheumatoid arthritis. Researchers want to understand how these vessels change with disease and with treatment. **You may be eligible if...** - You are 18 or older - You have been diagnosed with rheumatoid arthritis meeting standard diagnostic criteria - Your disease is currently active (joints are inflamed) - You are either newly diagnosed (within 1 year) and starting a new medication, OR have had the disease for 10+ years - You have active joint swelling in one or both hands confirmed by ultrasound **You may NOT be eligible if...** - Your rheumatoid arthritis is currently well-controlled with no active inflammation - You have other conditions affecting your lymphatic system Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIndocyanine green

A trained physician will inject 0.1 ml of the ICG in to the web spaces of the hands in both upper extremities.

DEVICEMultiSpectral Imaging System

Once the ICG is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.

Locations(1)

University of Rochester

Rochester, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05197530

Related Trials

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

NCT0691680637 locations

A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

NCT0697244696 locations

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

NCT0673393516 locations

Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD

NCT074235331 location

A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)

NCT0736359010 locations